Efficacy of Human Recombinant Growth Hormone in Females of a Non-Obese Hyperglycemic Mouse Model after Birth with Low Birth Weight
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126294 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Wataru Tokunaga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo 173-8610, Japan. Hauptthemen laut MEDLINE: Disease Models, Animal, Hyperglycemia, Insulin Resistance, Liver. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Nihon University Research Grant, Nihon University School of Medicine Alumni Association’s 60th anniversary fund research grant.
Abstract (Originalsprache)
We examined whether the administration of growth hormone (GH) improves insulin resistance in females of a non-obese hyperglycemic mouse model after birth with low birth weight (LBW), given that GH is known to increase muscle mass. The intrauterine Ischemia group underwent uterine artery occlusion for 15 min on day 16.5 of gestation. At 4 weeks of age, female mice in the Ischemia group were divided into the GH-treated (Ischemia-GH) and non-GH-treated (Ischemia) groups. At 8 weeks of age, the glucose metabolism, muscle pathology, and metabolome of liver were assessed. The insulin resistance index improved in the Ischemia-GH group compared with the Ischemia group (p = 0.034). The percentage of type 1 muscle fibers was higher in the Ischemia-GH group than the Ischemia group (p < 0.001); the muscle fiber type was altered by GH. In the liver, oxidative stress factors were reduced, and ATP production was increased in the Ischemia-GH group compared to the Ischemia group (p = 0.014), indicating the improved mitochondrial function of liver. GH administration is effective in improving insulin resistance by increasing the content of type 1 muscle fibers and improving mitochondrial function of liver in our non-obese hyperglycemic mouse model after birth with LBW.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo 173-8610, Japan.
- Jin Children's Clinic, Tokyo 145-0065, Japan.
ORCID-Profile: Nobuhiko Nagano, Shoichi Shimizu, Ichiro Morioka
Förderung
- Japan Society for the Promotion of Science
- Nihon University Research Grant
- Nihon University School of Medicine Alumni Association’s 60th anniversary fund research grant
- Grants-in-Aid for Young Scientists
- Scientific Research (C)
- Novo Nordisk Pharma Ltd. and Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics
Zitieren
APA
Tokunaga, W., Nagano, N., Matsuda, K., Nakazaki, K., Shimizu, S., Okuda, K., Aoki, R., Fuwa, K., Murakami, H., & Morioka, I. (2024). Efficacy of Human Recombinant Growth Hormone in Females of a Non-Obese Hyperglycemic Mouse Model after Birth with Low Birth Weight. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126294
Vancouver
Tokunaga W, Nagano N, Matsuda K, Nakazaki K, Shimizu S, Okuda K, et al. Efficacy of Human Recombinant Growth Hormone in Females of a Non-Obese Hyperglycemic Mouse Model after Birth with Low Birth Weight. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126294
BibTeX
@article{Tokunaga2024,
author = {Tokunaga, Wataru and Nagano, Nobuhiko and Matsuda, Kengo and Nakazaki, Kimitaka and Shimizu, Shoichi and Okuda, Koh and Aoki, Ryoji and Fuwa, Kazumasa and Murakami, Hitohiko and Morioka, Ichiro},
title = {Efficacy of Human Recombinant Growth Hormone in Females of a Non-Obese Hyperglycemic Mouse Model after Birth with Low Birth Weight},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126294}
}
EUVIMED